4.1 Review

Variations in FEV1 decline over time in chronic obstructive pulmonary disease and its implications

Journal

CURRENT OPINION IN PULMONARY MEDICINE
Volume 19, Issue 2, Pages 116-124

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCP.0b013e32835d8ea4

Keywords

chronic obstructive pulmonary disease; individual variability; rate of decline in forced expired volume in 1 s

Funding

  1. Boehringer-Ingelheim
  2. AstraZeneca
  3. GlaxoSmithKline
  4. Pfizer
  5. Novartis
  6. Forest Labs
  7. Pearl Therapeutics
  8. Chiesi
  9. Sunovion
  10. National Heart, Lung and Blood Institute

Ask authors/readers for more resources

Purpose of review This article reviews findings from longitudinal observational studies in both general and chronic obstructive pulmonary disease (COPD) populations, as well as from intervention trials in COPD, in which the annual rate of decline in forced expired volume in 1 s (FEV1) has been measured. The purpose of the review is to describe the individual variability in rates of decline in FEV1 within these populations, explore the factors contributing to this variability and discuss its implications. Recent findings Individual rates of decline in FEV1 have been found to vary considerably across participants with COPD in both observational cohorts and intervention trials from decreases as rapid as 150-200 ml per year to increases of up to approximately 150 ml per year, with mean rates of decline ranging from 33 to 69 ml per year. Aside from technical and biologic (e. g., time of day, season, weather, fatigue) sources of variation, other influential factors have included smoking status (most notably current versus former smoking), baseline smoking intensity, baseline lung function, airway hyperresponsiveness, exacerbation frequency, and, variably, age and sex. The presence of emphysema may also be a determinant, as well as certain biomarkers and gene variants. Summary The wide distribution of individual rates of decline in FEV1 includes especially rapid and slow declines. Future research is needed to identify biomarkers that both are predictive of a rapid decline within individuals who might then be targeted for special intervention and might also serve as surrogate endpoints in interventional trials.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available